focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-France gives hospital staff COVID shots as it plays catch-up with neighbours

Mon, 04th Jan 2021 08:29

* France criticised for slow vaccine roll-out

* French regulator: more information needed on AstraZeneca

* https://graphics.reuters.com/world-coronavirus-tracker-and-maps/
(Recasts, adds details)

By Sudip Kar-Gupta and Richard Lough

PARIS, Jan 4 (Reuters) - France is accelerating its COVID-19
vaccination of medical staff in hospitals, its health minister
said on Monday, after an initial roll-out that was slowed by
bureaucracy and precaution in one of the most vaccine-sceptical
countries in the world.

Health Minister Olivier Veran said several thousand COVID-19
shots developed by Pfizer and Germany's BioNTech
had been administered across France on Monday.

France was slow off the mark, delivering just 516 COVID-19
inoculations during the first week of a campaign that focused on
nursing home residents.

"We have decided to accelerate the campaign by widening the
target group to health staff without waiting to complete the
vaccination campaign in retirement homes," Veran said during a
visit to a Paris hospital.

The sluggish start compared with European neighbours such as
Britain and Germany irritated President Emmanuel Macron, who has
called a meeting with his prime minister and health minister on
Monday evening to speed up deployment of the vaccine.

Macron wanted to "put pressure on the system" and quicken
the vaccine's deployment, an Elysee official said.

"It's going too slowly," epidemiologist and government
adviser Arnaud Fontanet told France Info radio.

"But the real deadline is to reach 5-10 million
(vaccinations) by the end of March, because that's the point at
which you have a real impact on the spread of the virus."

The coronavirus has killed more than 65,000 people in
France, the seventh-highest national toll globally. Even so, a
survey over the weekend showed six in every 10 French citizens
intend to refuse vaccination.

Fontanet said it would be "useful" to simplify the
bureaucracy involved in the vaccination roll-out. He stopped
short of saying whether a mandatory consultation with a doctor
several days before getting a COVID jab was time wasted.

CAUTIOUS APPROACH

A slow vaccination campaign risks jeopardising France's
recovery from an unprecedented economic slump in a time of
peace.

France's National Academy of Medicine last week said the
government was taking "excessive precautions". Government
officials have said vaccinating in care homes was complex
logistically.

A spokesman for nursing home operator Korian said that the
company had been told to be ready for vaccinations at three of
its sites in the greater Paris area on Monday but that the doses
had not yet been delivered.

Britain, which has used more than a million COVID-19 vaccine
shots already, has now begun vaccinating its population with the
shot developed by Oxford University and AstraZeneca,
boasting a scientific triumph.

Dominique Le Guludec, head of France's medical regulator,
said there was still insufficient data to approve the
AstraZeneca vaccine.

"We prefer to wait another 15 days if necessary to have all
the data we need on safety and efficacy," Le Guludec told BFM
TV.

The EU's medical watchdog is expected to decide on approval
of a third vaccine, developed by Moderna, later this
week.

France on Monday sent 12 million pupils back to school after
the Christmas holidays as planned.

Restaurants, bars, museums and cinemas remain shut. It was
unlikely restaurants would re-open as initially planned on Jan.
20, government minister Alain Griset said on Sunday.
(Reporting by Sudip Kar-Gupta and Richard Lough; Additional
reporting by Michel Rose; Editing by Nick Macfie, Hugh Lawson,
William Maclean)

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.